News

Umicore and SiliCycle have entered into an exclusive sales representation agreement, under which SiliCycle will commercialize Umicore’ metalbased homogenous catalysts in the North American Life Science Industry. The

Partnerships between suppliers of customized organic-chemical syntheses for the early development stages of active pharmaceutical ingredients will take center stage at the BOS cmc industry forum, on the

SOCMA’s second annual Washington Fly-In, revolved around topics of teauthorizing chemical security rules, modernizing the Toxics Substances Control Act, and protecting workers’ rights threatened by Card Check discussed

CEL-SCI has announced that it is expanding the pre-clinical testing of its flu vaccine, utilizing its proprietary LEAPS technology (Ligand Epitope Antigen Presentation System). The testing is intended

Penwest, Endo and Valeant have announced that Endo has signed an exclusive license with Valeant allowing it to market Opana Er in Canada, Australia and New Zealand. Opana

Raptor has announced that it has signed a collaboration and licensing agreement with Roche to evaluate therapeutic delivery across the blood-brain barrier (BBB), starting with Raptor’s proprietary NeuroTrans

Arete has announced the presentation of three posters of AR9281, an orally-administered soluble epoxide hydrolase (sEH) inhibitor, which is in a Phase II clinical program. The drug will

Morphotek announced that FDA has cleared its investigational new drug (IND) application to study MORAb-004, for the treatment of patients with solid tumors. MORAb-004 targets endosialin, a protein

Roche has announced that it will start phase III clinical investigations for aleglitazar, its innovative PPAR co-agonist R1439 which is uniquely designed to reduce cardiovascular morbidity and mortality